Publication

Back to overview

High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Chihota Belinda V, Wandeler Gilles, Chilengi Roma, Mulenga Lloyd, Chung Raymond T, Bhattacharya Debika, Egger Matthias, Vinikoor Michael J,
Project Forschungspauschale Forschungsratspräsident SNF
Show all

Original article (peer-reviewed)

Journal The Journal of Infectious Diseases
Volume (Issue) 221(2)
Page(s) 218 - 222
Title of proceedings The Journal of Infectious Diseases

Open Access

URL https://boris.unibe.ch/134086/
Type of Open Access Green OA Embargo (Freely available via Repository after an embargo)

Abstract

AbstractAmong 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.
-